Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes

Molecular and Cellular Biology

Volumn 19, Issue 2, 1999, Pages 1068-1080

  Adams, Peter D ^a   Li, Xiaotong ^a   Sellers, William R ^a   Baker, Kayla B ^a,b   Leng, Xiaohong ^c   Harper, J Wade ^c   Taya, Yoichi ^d   Kaelin Jr , William G ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING;

ANIMALIA;

EID: 0032929012     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.19.2.1068     Document Type: Article

References (100)

1. Adams, P. D., and W. G. Kaelin. 1995. Transcriptional control by E2F. Semin. Cancer Biol. 6:99-108.
2. Adams, P. D., W. R. Sellers, S. K. Sharma, A. D. Wu, C. M. Nalin, and W. G. Kaelin. 1996. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cdk inhibitors. Mol. Cell. Biol. 16:6623-6633.
3. Bartkova, J., J. Lukas, H. Muller, D. Lutzhoft, M. Strauss, and J. Bartek. 1994. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57:353-361.
4. Botz, J., K. Zerfass-Thome, D. Spitzovsky, H. Delius, B. Vogt, M. Eilers, A. Hatzigeorgiou, and P. Jansen-Durr. 1996. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol. Cell. Biol. 16:3401-3409.
5. Cantley, L. C., K. R. Auger, C. Carpenter, B. Duckworth, A. Graziani, R. Kapeller, and S. Soltoff. 1991. Oncogenes and signal transduction. Cell 64:281-302.
6. Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752.
7. Chen, J., P. Saha, S. Kornbluth, B. D. Dynlacht, and A. Dutta. 1996. Cyclin binding motifs are essential tor the function of p21cip1. Mol. Cell. Biol. 16:4673-4682.
8. Cobrinik, D., P. Whyte, D. S. Peeper, T. Jacks, and R. A. Weinberg. 1993. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 7:2392-2404.
9. Connell-Crowley, L., J. W. Harper, and D. W. Goodrich. 1997. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell 8:287-301.
10. DeCaprio, J. A., Y. Furukawa, F. Ajchenbaum, J. Griffen, and D. M. Livingston. 1992. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc. Natl. Acad. Sci. USA 89:1795-1798.
11. DeGregori, J., G. Leone, K. Ohtani, A. Miron, and J. R. Nevins. 1995. E2F1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 9:2873-2887.
12. Dowdy, S. F., P. W. Hinds, K. Louie, S. I. Reed, A. Arnold, and R. A. Weinberg. 1993. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499-511.
13. Duronio, R. J., A. Brook, N. Dyson, and P. H. O'Farrell. 1996. E2F induced S phase requires cyclin E. Genes Dev. 10:2505-2513.
14. Duronio, R. J., and P. H. O'Farrell. 1995. Developmental control of the G1 to S transition in Drosophila: cyclin E is a limiting downstream target of E2F. Genes Dev. 9:1456-1468.
15. Dynlacht, B. D., Flores, O., Lees, J. A. Harlow, E. 1994. Differential regulation of E2F transactivation by cyclin/cdk complexes. Genes Dev. 8:1772-1786.
16. Dynlacht, B. D., K. Moberg, J. A. Lees, E. Harlow, and L. Zhu. 1997. Specific Regulation of E2F family members by cyclin-dependent kinases. Mol. Cell. Biol. 17:3867-3875.
17. Ewen, M. E., B. Faha, E. Harlow, and D. M. Livingston. 1992. Interaction of p107 with cyclin A independent of complex formation with viral oncoproteins. Science 255:85-87.
18. Ewen, M. E., H. K. Sluss, C. J. Sherr, H. Matsushime, J.-Y. Kato, and D. M. Livingston. 1993. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497.
19. Ezhevsky, S., H. Nagahara, A. Vocero-Akbani, D. Gius, M. Wei, and S. Dowdy. 1997. Hypo-phosphorylation protein (pRb) by cyclin D:Cdk/6 complexes results in active pRb. Proc. Natl. Acad. Sci. USA 94:10699-10704.
20. Fagan, R., Flint, K. J., Jones, N. 1994. Phosphorylation of E2F1 modulates its interaction with the retinoblastoma gene product and the adenoviral E4 19kD protein. Cell 78:799-811.
21. Faha, B., M. Ewen, L. Tsai, D. M. Livingston, and E. Harlow. 1992. Interaction between human cyclin A and adenovirus E1A-associated p107 protein. Science 255:87-90.
22. Frangioni, J., and B. G. Neel. 1993. Solubilisation and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. Anal. Biochem. 210:179-187.
23. Geng, Y., E. N. Eaton, M. Picon, J. M. Roberts, A. S. Lundberg, A. Gifford, C. Sardet, and R. A. Weinberg. 1996. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12:1173-1180.
24. Gu, Y., C. W. Turek, and D. O. Morgan. 1993. Inhibition of cdk2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707-710.
25. Guan, K.-L., C. W. Jenkins, Y. Li, M. A. Nichols, X. Wu, C. L. O'Keefe, A. G. Matera, and Y. Xiong. 1994. Growth suppression by p18, a p16 INK4/MTS1 and p14 INK4B/MTS1-relaled CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8:2939-2952.
26. Gupta, S., T. Barrett, A. J. Whitmarsh, J. Cavanagh, H. K. Sluss, B. Derijard, and R. J. Davis. 1996. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:2760-2770.
27. Hall, M., and G. Peters. 1996. Genetic alterations of cyclins, cyclin dependent kinases, and Ddk inhibitors in human cancer. Adv. Cancer Res. 68: 67-108.
28. Hamel, P. A., B. L. Cohen, L. M. Sorce, B. L. Gallie, and R. A. Phillips. 1990. Hyperphosphorylation of the retinoblastoma gene product is determined by domains outside the simian virus 40 large-T-antigen-binding regions. Mol. Cell. Biol. 10:6586-6595.
29. Hamel, P. A., R. M. Gill, R. A. Phillips, and B. L. Gallie. 1992. Regions controlling hyperphosphorylation and conformation of the retinoblastoma gene product are independent of domains required for transcriptional repression. Oncogene 7:693-701.
30. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 cdk-interacting protein CIP1 is a potent inhibitor of G1 Cyclin-dependent kinases. Cell 75:805-816.
31. Hatakeyama, M., J. Brill, G. Fink, and R. Weinberg. 1994. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev. 8:1759-1771.
32. 1 restriction point regulation in Rb-deficient fibroblasts. Mol. Cell. Biol. 16:2402-2407.
33. Hiebert, S. W. 1993. Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol. Cell. Biol. 13:3384-3391.
34. Hinds, P. W., S. Mittnacht, V. Dulic, A. Arnold, S. I. Reed, and R. A. Weinberg. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006.
35. Hoang, A., B. Lutterbach, B. C. Lewis, T. Yano, T. Y. Chou, J. F. Barrett, M. Raffeld, S. R. Hann, and C. V. Dang. 1995. A link between increased transforming activity of lymphoma derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-myc transactivation domain. Mol. Cell. Biol. 15:4031-4042.
36. Holmes, J. K., and M. J. Solomon. 1996. A predictive scale for evaluating cyclin-dependent kinase substrates. J. Biol. Chem. 41:25240-25246.
37. Horton, L. E., Y. Qian, and D. J. Templeton. 1995. G1 cyclins control the retinoblastoma gene product growth regulation activity via upstream mechanisms. Cell Growth Differ. 6:395-407.
38. Hunter, T., and J. Pines. 1991. Cyclins and cancer. Cell 66:1071-1074.
39. Hunter, T., and J. Pines. 1994. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582.
40. Hurford, R. K., D. Cobrinik, M.-H. Lee, and N. Dyson. 1997. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev. 11:1447-1463.
41. Kaelin, W. G. 1997. Recent insights into the functions of the retinoblastoma gene product. Cancer Investig. 15:243-254.
42. Kallunki, T., T. Deng, M. Hibi, and M. Karin. 1996. c-jun can recruit JNK to phosphorylate dimerisation partners via specific docking interactions. Cell 87:929-39.
43. Kato, J.-Y., H. Matsushime, S. W. Hiebert, M. E. Ewen, and C. J. Sherr. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase cdk4. Genes Dev. 7:331-342.
44. Kaye, F. J., R. A. Kratzke, J. L. Gerster, and J. M. Horowitz. 1990. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA 87: 6922-6926.
45. Kelly, B., K. Wolfe, and J. Roberts. 1998. Identification of a substrate-targeting domain in cyclin E necessary for phosphorylation of the retinoblastoma protein. Proc. Natl. Acad. Sci. USA 95:2535-2540.
46. Kitagawa, M., H. Higashi, H.-K. Jung, I. Suzuki-Takahashi, M. Ikeda, K. Tamai, J. Kato, K. Seqawa, E. Yoshida, S. Nishimura, and Y. Taya. 1996. The consensus motif for phosphorylation by cyclin D1-cdk4 is different from that for phosphorylation by cyclin A/E-cdk2. EMBO J. 15:7060-7069.
47. Knudsen, E. S., C. Buckmaster, T.-T. Chen, J. R. Feramisco, and J. Y. J. Wang. 1998. Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev. 12:2278-2821.
48. Knudsen, E. S., and J. Y. Wang. 1996. Differential regulation of retinoblastoma function by specific cdk phosphorylation sites. J. Biol. Chem. 271: 8313-20.
49. Knudsen, E. S., and J. Y. J. Wang. 1997. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol. Cell. Biol. 17:5771-5783.
50. Koh, J., G. Enders, B. Dynlacht, and E. Harlow. 1995. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-510.
51. Krek, W., M. Ewen, S. Shirodkar, Z. Arany, W. G. Kaelin, and D. M. Livingston. 1994. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 78:1-20.
52. LaBaer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
53. Lees, E., B. Faha, V. Dulic, S. I. Reed, and E. Harlow. 1992. Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev. 6:1874-1885.
54. Lees, J. A., K. J. Buchkovich, D. R. Marshak, C. W. Anderson, and E. Harlow. 1991. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J. 10:4279-4290.
55. Leng, X., L. Connell-Crowley, D. Goodrich, and J. W. Harper. 1997. S-phase entry upon ectopic production of G1 cyclin-dependent kinases in the absence of retinoblastoma phosphorylation. Curr. Biol. 7:709-712.
56. Leone, G., J. DeGregori, R. Sears, L. Jakoi, and J. R. Nevins. 1997. Myc and Ras collaborate in inducing accumulation of active cyclin E/cdk2 and E2F. Nature 387:422-426.
57. Li, Y., C. Graham, S. Lacy, A. M. V. Duncan, and P. Whyte. 1993. The adenovirus E1A-associated 130-kd protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. Genes Dev. 7:2366-2377.
58. Lin, B. T.-Y., S. Gruenwald, A. O. Moria, W.-H. Lee, and J. Y. J. Wang. 1991. Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J. 10:857-864.
59. Lisztwan, J., A. Marti, H. Sutterluty, M. Gstaiger, C. Wirbelauer, and W. Krek. 1998. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway. EMBO 17:368-383.
60. Lukas, J., T. Herzinger, K. Hansen, M. C. Moroni, D. Resnitzky, I. Helin, S. I. Reed, and J. Bartek. 1997. Cyclin E induced S phase without activation of the Rb/E2F pathway. Genes Dev. 11:1479-1492.
61. Lukas, J., D. Parry, L. Aargaard, D. J. Mann, J. Bartkova, M. Strauss, G. Peters, and J. Bartek. 1995. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375:503-506.
62. Lukas, J. B., J. Rohde, M. Strauss, and J. Bartek. 1995. Cyclin D1 is dispensable for G1 control in retinoblastoma gene deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15:2600-2611.
63. Lundberg, A., and R. Weinberg. 1998. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 18:743-761.
64. Marsilio, E., S. H. Cheng, B. Schaffhausen, E. Paucha, and D. M. Livingston. 1991. The T/t common region of simian virus 40 large T antigen contains a distinct transformation-governing sequence. J. Virol. 65:5647-5652.
65. Mitchison, T. J. 1989. Mitosis: basic concepts. Curr. Opin. Cell Biol. 1:67-74.
66. Mittnacht, S. 1998. Control of pRB phosphorylation. Curr. Opin. Genet. Dev. 8:21-27.
67. Moreno, S., and P. Nurse. 1990. Substrates for p34cdc2: in vivo veritas. Cell 61:549-551.
68. Muller, H., J. Lukas, A. Schneider, P. Warthoe, J. Bartek, M. Eilers, and M. Strauss. 1994. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl. Acad. Sci. USA 91:2945-2949.
69. Nevins, J. R. 1992. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429.
70. Nigg, E. 1991. The substrates of the cdc2 kinase. Semin. Cell. Biol. 2:261-270.
71. Norbury, C., and P. Nurse. 1992. Animal cell cycles and their control. Annu. Rev. Biochem. 61:441-470.
72. Ohtani, K., J. DeGregori, and J. R. Nevins. 1995. Regulation of the cyclin E gene by transcription factor E2F1. Proc. Natl. Acad. Sci. USA 92:12146-12150.
73. 1/S phase transition. Mol. Cell. Biol. 15:2612-2624.
74. Pan, W., T. Sun, R. Hoess, and R. Grafstrom. 1998. Defining the minimal portion of the retinoblastoma protein that serves as an efficient substrate for cdk4 kinase/cyclin D1 complex. Carcinogenesis 19:765-769.
75. Peeper, D. S., P. Keblusek, K. Helin, M. Toebes, A. J. van der Eb, and A. Zantema. 1995. Phosphorylation of a specific site in E2F1 affects its electrophoretic mobility and promotes pRB binding in vitro. Oncogene 10:39-48.
76. Peeper, D. S., L. L. Parker, M. E. Ewen, M. Toebes, F. L. Frederick, M. Xu, A. Zantema, A. J. van der Eb, and H. Piwnica-Worms. A- and B-type cyclins differentially modulate substrate specificity of cyclin-CDK complexes. EMBO J., in press.
77. Polyak, K., M. Lee, H. Erdjument-Bromage, A. Koff, J. Roberts, P. Tempst, and J. Massague. 1994. Cloning of p27kip1, a cyclin dependent kinase inhibitor and a potential mediator of extracellular mitogenic signals. Cell 78:59-66.
78. Qin, X.-Q., T. Chittenden, D. M. Livingston, and W. G. Kaelin. 1992. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6:953-964.
79. Russo, A. A., P. D. Jeffrey, A. K. Patten, J. Massague, and N. P. Pavletich. 1996. Crystal structure of the p27kip1 cyclin dependent kinase inhibitor bound to the cyclin A-cdk2 complex. Nature 382:325-331.
80. Schulman, B., D. Lindstrom, and E. Harlow. 1998. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc. Natl. Acad. Sci. USA 95:10453-10458.
81. Sellers, W. R., B. G. Novitch, S. Miyake, A. Heith, G. A. Otterson, F. J. Kaye, A. Lassar, and W. G. Kaelin. 1998. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev. 12:95-106.
82. Sherr, C. 1993. Mammalian G1 cyclins. Cell 73:1059-1065.
83. Songyang, Z., S. Blechner, N. Hoagland, M. F. Hoekstra, H. Piwnica-Worms, and L. C. Cantley. 1994. Use of an orientated peptide library to determine the optimal substrates of protein kinases. Curr. Biol. 4:973-982.
84. Soucek, T., O. Pusch, E. Hengstschlager-Ottnad, P. D. Adams, and M. Hengstschlager. 1997. Deregulated Expression of E2F1 induces cyclin A- and E-associated kinase activities independently from cell cycle position. Oncogene 14:2251-2257.
85. Srinivasan, J., M. Koszelak, M. Mendelow, Y.-G. Kwon, and D. S. Lawrence. 1995. The design of peptide based substrates for the cdc2 protein kinase. Biochem. J. 309:927-931.
86. Taya, Y. Unpublished data.
87. Templeton, D. J., S. H. Park, L. Lanier, and R. Weinberg. 1991. Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering. Proc. Natl. Acad. Sci. USA 88:3033-3037.
88. Toyoshima, H., and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin/cdk protein kinase activity is related to p21. Cell 78:67-74.
89. van den Heuvel, S., and E. Harlow. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262:2050-2053.
90. Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
91. Williams, R. T., D. A. Carbonaro-Hall, and F. L. Hall. 1992. Co-purification of p34 cdc2/p58cyclin A proline-directed protein kinase and the retinoblastoma tumor susceptibility gene product: interaction of an oncogenic serinethreonine protein kinase with a tumor-suppressor protein. Oncogene 7:423-432.
92. Wilson, I. A., D. H. Haft, E. D. Getzoff, J. A. Tainer, R. A. Lerner, and S. Brenner. 1985. Identical short peptide sequences in unrelated proteins can have different confirmations: a testing ground for theories of immune recognition. Proc. Natl. Acad. Sci. USA 82:5255-5259.
93. Xiong, Y., H. Zhang, and D. Beach. 1993. Subunit rearrangement of the cyclin dependent kinases is associated with cellular transformation. Genes Dev. 7:1572-1583.
94. Xiong, Y., G. Hannon, H. Zhang, D. Casso, R. Kabayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
95. Xu, M., K. A. Sheppard, C.-Y. Peng, A. S. Yee, and H. Piwnica-Worms. 1994. Cyclin A/cdk2 binds directly to E2F1 and inhibits the DNA-binding activity of E2F1/DP1 by phosphorylation. Mol. Cell. Biol. 14:8420-8431.
96. Zarkowska, T., and S. Mittnacht. 1997. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J. Biol. Chem. 272:12738-12746.
97. Zhang, H., G. J. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1750-1758.
98. Zhang, J., R. J. Sanchez, S. Wang, C. Guarnaccia, A. Tossi, S. Zahariev, and S. Pongor. 1994. Substrate specificity of cdc2 kinase from human HeLa cells as determined with synthetic peptides and molecular modelling. Arch. Biochem. Biophys. 315:415-424.
99. Zhao, Y., C. Bjorbaek, and D. E. Moller. 1996. Regulation and Interaction of pp90(rsk) isoforms with mitogen-activated protein kinases. J. Biol. Chem. 271:29773-29779.
100. Zhu, L., E. Harlow, and B. D. Dynlacht. 1995. p107 uses a p21/CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev. 9:1740-1752.